A Meta-analysis of Haemorrhage with Ticlopidine and Clopidogrel Following Coronary Artery Stent Placement

META-ANALYSIS, July 2012, VOL II ISSUE II, ISSN 2042-4884
5083/ejcm.20424884.80 , Cite or Link Using DOI
Creating a Digital Object Identifier Link

A digital object identifier (DOI) can be used to cite and link to electronic documents. A DOI is guaranteed never to change, so you can use it to link permanently to electronic documents.

To find a document using a DOI

  1. Copy the DOI of the document you want to open.
    The correct format for citing a DOI is as follows: doi:10.1016/S0140-6736(08)61345-8
  2. Open the following DOI site in your browser:
    dx.doi.org
  3. Enter the entire DOI citation in the text box provided, and then click Go.
    The document that matches the DOI citation will display in your browser window.

The DOI scheme is administered by the International DOI Foundation. Many of the world's leading publishers have come together to build a DOI-based document linking scheme known as CrossRef.

Kathlyn J Ronaldson BSc MSc DPhil MPH, Louisa L Lam BHSc GradDip(CC) MPH, Shelly Rodrigo MSc MPhil PhD, Andrew M Tonkin MBBS MD FRACP

Background: Clopidogrel has largely replaced ticlopidine in antiplatelet therapy after coronary artery stenting because of the higher risk of blood dyscrasias with the latter agent. However, haemorrhage in this setting is not a rare event. We aimed to investigate by meta-analysis the risk of haemorrhage with ticlopidine plus aspirin versus clopidogrel plus aspirin after coronary artery stenting.

Methods: A literature search was conducted for studies comparing ticlopidine plus aspirin with clopidogrel plus aspirin in patients undergoing coronary artery stenting procedures. Studies were included in the meta-analysis if they provided data on haemorrhage for both therapies.

Results: Seven randomised and 5 non-randomised studies met the entry criteria. After adjustment for a significant imbalance in use of abciximab in one study, the total number of haemorrhages was 82 with ticlopidine (among 4093 patients) and 78 for clopidogrel (among 3714 patients). Meta-analysis found that ticlopidine plus aspirin was associated with a lower risk of haemorrhage than clopidogrel plus aspirin (odds ratio 0.69; 95% confidence interval 0.50-0.97; p=0.03).

In the studies providing information on these events, the rate of blood dyscrasias was higher with ticlopidine than with clopidogrel (0.66% vs 0.45%), but this was offset by the lower rate of haemorrhage with ticlopidine (0.71% vs 1.00%).

Conclusion: This meta-analysis found that ticlopidine plus aspirin was associated with a significantly lower risk of haemorrhage than clopidogrel plus aspirin after coronary artery stenting. Given the similar efficacy of the two regimens, it may be worth reconsidering the role of ticlopidine as an antiplatelet therapy.